Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, focuses on the development of cannabinoid-based prescription medicines. Its lead drug candidate
is OCT461201, a selective CB2 agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing an unmodified phytocannabinoid combination for orphan indications in neuropathic pain. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom. The company trades on MAIN MARKET exchange marketplace. The company headquarter is located in London, United Kingdom. The company was established in the 2021. As of writing, the company status seems to be inactive, which indicates it may not be actively trading on the stock exchanges and may be delisted/merged/suspended/renamed.
| Ticker | OCTP |
| Long Name | Oxford Cannabinoid Technologies Holdings Plc |
| Short Name | Oxford Cannabinoid Technologies |
| Sector | Healthcare |
| Subsector | Biotechnology |
| Subsector 2 | |
| Currency | GBX |
| ISIN | |